Stockwatch: Burying products that fade to black
This article was originally published in Scrip
There is a little-recognised category of development pharmaceutical products that seem to hang around for years, having very slow progress through clinical trials and then one day, they quietly disappear all together from the company’s pipeline. One renowned London-based fund manager used to honor the practice with the phrase “pharma buries its dead at night”. This used to be quite true up to about 2003, but the rise of the patent cliff has brought greater scrutiny to pharmaceutical companies’ pipelines.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.